Back
Sodium glucose type 2 inhibitors (SGLT2i) changed the treatment of chronic kidney disease (CKD) and have become one of the most relevant findings in the history of nephrology. Over the last decade, SGLT2i have been shown to reduce major kidney events (MAKE) by 40% in people with or without diabetes. It is being explored whether this benefit expands to other more specific kidney conditions, such as hospitalized critically ill patients or with acute kidney injury (AKI) due to its mechanism of action, which, in theory, could attenuate and protect the nephron from new insults, promoting its recovery. Hence, there may be an association between administration of SGLT2i during AKI and the incidence MAKE in the short and intermediate term.
In this retrospective cohort study, included patients who had AKI and received SGLT2i during the hospitalization, then compared versus those without. Analyzed the association between AKI and SGLT2i use with the outcomes as MAKE at 10, 30-90 days, each of the MAKE components and especified patients subgroups.
In this retrospective cohort, we observed that hospitalized patients with AKI who consumed SGLT2i, compared to those who did not, had no association in the risk of developing MAKE at 10 or 30-90 days, neither in its individual components, although it may be that some specific subgroups could benefit from its use.